Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Proparacaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 4/20 | 0.98 |
| ▸ | SCN2A known ✓ | Q99250 | 4/20 | 0.98 |
| ▸ | SCN3A known ✓ | Q9NY46 | 4/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | MAOA | P21397 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | RAD52 | P43351 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 4/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | HTR3A | P46098 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proparacaine SCHEMBL23333 | 1.00 | CYP2D6 (0.98) | CYP2D6SCN1ASCN2ASCN3ACYP1A2 | |
| Proparacaine SCHEMBL9872795 | 1.00 | CYP2D6 (0.98) | CYP2D6SCN1ASCN2ASCN3ACYP1A2 | |
| Proparacaine SCHEMBL93880 | 1.00 | CYP2D6 (0.98) | CYP2D6SCN1ASCN2ASCN3ACYP1A2 | |
| Proparacaine SCHEMBL29805494 | 0.99 | CYP2D6 (1.00) | CYP2D6SCN1ASCN2ASCN3ACYP1A2 | |
| Proparacaine SCHEMBL23334 | 0.99 | CYP2D6 (1.00) | CYP2D6SCN1ASCN2ASCN3ACYP1A2 | |
| Proparacaine SCHEMBL20641500 | 0.96 | CYP2D6 (0.91) | CYP2D6SCN1ASCN2ASCN3ACYP1A2 | |
| Proparacaine SCHEMBL9419527 | 0.95 | CYP2D6 (0.89) | CYP2D6SCN1ASCN2ASCN3ACYP1A2 | |
| Proparacaine SCHEMBL11131964 | 0.95 | CYP2D6 (0.89) | CYP2D6SCN1ASCN2ASCN3ACYP1A2 | |
| Proparacaine SCHEMBL10981263 | 0.88 | CYP2D6 (0.76) | CYP2D6SCN1ASCN2ASCN3ACYP1A2 | |
| Betoxycaine SCHEMBL25758 | 0.86 | CYP2D6 (0.77) | CYP2D6SCN1ASCN2ASCN3ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024228496-A1 | NON-FLUORESCENT COMPOUND AND USES THEREOF | 에스에프씨 주식회사 | 2024-11-07 | — | — | WO | claimed |
| WO-2024225787-A1 | NOVEL COMPOUND AND USE THEREOF | 에스에프씨 주식회사 | 2024-10-31 | — | — | WO | claimed |
| US-20250275983-A1 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | Sydnexis, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250186478-A1 | METHODS AND COMPOSITIONS FOR TARGETED GENE TRANSFER | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250186251-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | Sydnexis, Inc. | 2025-06-12 | — | — | US | disclosed |
| US-12168017-B2 | D2O stabilized pharmaceutical formulations | Sydnexis, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| WO-2024228496-A1 | NON-FLUORESCENT COMPOUND AND USES THEREOF | 에스에프씨 주식회사 | 2024-11-07 | — | — | WO | disclosed |
| US-12070466-B2 | D2O stabilized pharmaceutical formulations | Sydnexis, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-118453493-A | D2O-stabilized pharmaceutical formulations | 西德奈克西斯公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20230381016-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | Sydnexis, Inc. | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186251-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | CHRM3, CHRM2, CHRM4 | SCN1A 2291/4885SCN2A 2254/4885SCN3A 1604/4885 |
| US-12070466-B2 | D2O stabilized pharmaceutical formulations | AQP1, AQP3, CRYZ | SCN1A 2438/4885SCN2A 2910/4885SCN3A 2687/4885 |
| US-12168017-B2 | D2O stabilized pharmaceutical formulations | AQP1, AQP3, CRYZ | SCN1A 2438/4885SCN2A 2910/4885SCN3A 2687/4885 |
| US-20250275983-A1 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | AQP1, AQP3, CRYZ | SCN1A 2438/4885SCN2A 2910/4885SCN3A 2687/4885 |
| US-20230381016-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | CHRM3, CHRM2, CHRM4 | SCN1A 2291/4885SCN2A 2254/4885SCN3A 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.